Comparison of the Cardiovascular Response to Sedation with Dexmedetomidine, Midazolam, and Etomidate in Phacoemulsification under Local Topical Anesthesia; A Double-Blind Randomized Controlled Clinical Trial

局部麻醉下行超声乳化术中,右美托咪定、咪达唑仑和依托咪酯镇静对心血管反应的比较:一项双盲随机对照临床试验

阅读:1

Abstract

BACKGROUND: The present study aimed to compare the cardiovascular response to sedation with dexmedetomidine, midazolam, and etomidate during phacoemulsification under local Topical anesthesia. MATERIALS AND METHODS: In this double-blind randomized clinical trial, a total of 90 cataract surgery candidates undergoing phacoemulsification were selected and divided into three groups. The first group received 1 µg/kg dexmedetomidine over 10 minutes, followed by an infusion of dexmedetomidine at a rate of 0.5 µg/kg/h. The second group received 0.05 mg/kg midazolam, and the third group received 0.2 mg/kg slow IV etomidate. Hemodynamic parameters, sedation level, and adverse effects were recorded before anesthesia, during surgery, and during recovery. RESULTS: The results of this study showed that in the 10(th) minute of surgery, the systolic blood pressure (SBP) in the etomidate group was significantly higher than the other groups P value = 0.029). The pulse rate (PR) in the etomidate group at the 15(th) minute during surgery, 10(th), 20(th), and 30(th) minute in the recovery period (mean 70.33 ± 10.34 bpm, 72.10 ± 10.18 bpm, 73.70 ± 10.18 bpm, and 75.03 ± 6.73 bpm, respectively) was significantly higher than the other two groups (P value < 0.05). No adverse effects such as dizziness, restlessness, vomiting, or nausea were observed in the midazolam group. However, decreased heart rate was significantly higher in the dexmedetomidine group (26.7%) compared to the etomidate (3.3%) and midazolam (6.7%) groups (P value = 0.021). CONCLUSION: According to the results of this study, the sedation level achieved by dexmedetomidine, midazolam, and etomidate was similar. However, etomidate seemed to have a better effect on maintaining blood pressure and pulse rate compared to the other two drugs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。